Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Microbiotix

Drug Profile

Research programme: antibacterials - Microbiotix

Alternative Names: 259C; AcrAB-TolC efflux pump inhibitors - Microbiotix; Aminospectinomycins - Microbiotix; AU-FQ hybrids; bIAI compounds; bis-imidazolinylindole compound series; Fatty acid biosynthesis (FAB) pathway inhibitors - Microbiotix; Inhibitors of DnaA initiator protein - Microbiotix; Inhibitors of initiation of DNA replication - Microbiotix; Inhibitors of wall teichoic acid (WTA) - Microbiotix; MBX 1158; MBX 1162; MBX 1196; MBX 1337; MBX 1339; MBX 1641; MBX 2319 analogues - Microbiotix; MBX 3132; MBX 3795; MBX 3796; MBX 3797; MBX 4191; MBX-500; Sortase A (SrtA) inhibitors for Gram-positive infections - Microbiotix; SOS induction inhibitors - Microbiotix; Spectinamide antibacterials for MDR/XDR tuberculosis - Microbiotix; Spectinomycin analogues - Microbiotix; T3SS inhibitors; TTSS inhibitors; Tuberculosis therapies - Microbiotix

Latest Information Update: 19 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Microbiotix
  • Developer GLSynthesis; Microbiotix
  • Class Acetamides; Amidines; Aminocyclitols; Carboxylic acids; Coumarins; Heterocyclic compounds; Imidazoles; Indoles; Pyrans; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA helicase inhibitors; DNA helicase-primase inhibitors; DNA synthesis inhibitors; DNA-binding protein inhibitors; DNA-directed DNA polymerase inhibitors; Lipoteichoic acid inhibitors; Membrane protein inhibitors; Sortase A inhibitors; Toll-like receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Gram-negative infections
  • No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections; Tuberculosis

Most Recent Events

  • 11 Jun 2018 Preclinical development development is ongoing in Bacterial infections in USA
  • 07 Jun 2018 Pharmacodynamics data from a preclinical studies in Gram-negative infections presented at the ASM Microbe 2018
  • 07 Jun 2018 Pharmacodynamics data from in vitro study presented at the ASM Microbe (ASMM-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top